Researchmoz added Most up-to-date research on "Pharma Point: Overview Of Dermatology Therapeutics Drug Development Market" to its huge collection of research reports.
Dermatological conditions are one of the most
common types of disorders worldwide, and approximately one-third of the
US population suffers from at least one active skin condition. For the
past decades, the majority of the dermatology market has remained
saturated with established and generic products. However, the clinical
and commercial success of biologics in the treatment of psoriasis, as
well as advancements in the understanding of the disease pathways of
many dermatological conditions, have led to a renewed interest from
pharmaceutical companies in the dermatology market, and subsequently the
emergence of an innovative pipeline.
There are over 800 products in active development in the dermatology therapy area, with the majority of products being small molecules. Biologics represent approximately 40% of the pipeline, despite the fact that this molecule type represents only a small fraction of the marketed products landscape.
Overall, the dermatology pipeline is highly innovative, owing to the advancements in the understanding of the disease pathways of many skin disorders. The number of strong late-stage products and substantial early-stage segment of this active and diverse pipeline are strong indicators of long-term growth in this market.
To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=984798
The report provides comprehensive information on the pipeline development landscape for is Acne vulgaris, Psoriasis and Atopic dermatitis, from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.
Scope
Reasons to buy
There are over 800 products in active development in the dermatology therapy area, with the majority of products being small molecules. Biologics represent approximately 40% of the pipeline, despite the fact that this molecule type represents only a small fraction of the marketed products landscape.
Overall, the dermatology pipeline is highly innovative, owing to the advancements in the understanding of the disease pathways of many skin disorders. The number of strong late-stage products and substantial early-stage segment of this active and diverse pipeline are strong indicators of long-term growth in this market.
To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=984798
The report provides comprehensive information on the pipeline development landscape for is Acne vulgaris, Psoriasis and Atopic dermatitis, from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.
Scope
- Which companies are the most active within the pipeline for dermatology?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Table of Contents
GBI Research Report Guidance 2
Executive Summary 3
Table of Contents 4
List of Tables 6
List of Figures 13
Introduction 15
GBI Research Report Coverage 15
Acne Vulgaris Overview 15
Psoriasis Overview 15
Atopic Dermatitis Overview 15
Therapeutics Development 16
Acne Vulgaris 16
Psoriasis 18
Atopic Dermatitis 20
Therapeutics under Development by Companies 22
Acne Vulgaris 22
Psoriasis 24
Atopic Dermatitis 31
Therapeutics under Investigation by Universities/Institutes 34
GBI Research Report Guidance 2
Executive Summary 3
Table of Contents 4
List of Tables 6
List of Figures 13
Introduction 15
GBI Research Report Coverage 15
Acne Vulgaris Overview 15
Psoriasis Overview 15
Atopic Dermatitis Overview 15
Therapeutics Development 16
Acne Vulgaris 16
Psoriasis 18
Atopic Dermatitis 20
Therapeutics under Development by Companies 22
Acne Vulgaris 22
Psoriasis 24
Atopic Dermatitis 31
Therapeutics under Investigation by Universities/Institutes 34
No comments:
Post a Comment